Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hidradenitis suppurativa
Robert Sabat, Gregor B. E. Jemec, Łukasz Matusiak, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 415

Showing 1-25 of 415 citing articles:

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 394
Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases
Md. Rayhan Mahmud, Sharmin Akter, Sanjida Khanam Tamanna, et al.
Gut Microbes (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 215
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi, et al.
The Lancet (2023) Vol. 401, Iss. 10378, pp. 747-761
Closed Access | Times Cited: 186
What causes hidradenitis suppurativa ?—15 years after
Christos C. Zouboulis, Farida Benhadou, Angel S. Byrd, et al.
Experimental Dermatology (2020) Vol. 29, Iss. 12, pp. 1154-1170
Open Access | Times Cited: 147
Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis
Jóhann E. Guðjónsson, Lam C. Tsoi, Feiyang Ma, et al.
JCI Insight (2020) Vol. 5, Iss. 19
Open Access | Times Cited: 144
Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System
Georgios Kokolakis, Kerstin Wolk, Sylke Schneider‐Burrus, et al.
Dermatology (2020) Vol. 236, Iss. 5, pp. 421-430
Open Access | Times Cited: 140
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
Hideyuki Ujiie, David Rosmarin, Michael P. Schön, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 112
Disease modification in inflammatory skin disorders: opportunities and challenges
Thomas Bieber
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 662-680
Closed Access | Times Cited: 43
Hidradenitis suppurativa
Robert Sabat, Afsáneh Alavi, Kerstin Wolk, et al.
The Lancet (2025)
Open Access | Times Cited: 2
Aetiology and pathogenesis of hidradenitis suppurativa
Kerstin Wolk, Olivier Join‐Lambert, Robert Sabat
British Journal of Dermatology (2020) Vol. 183, Iss. 6, pp. 999-1010
Open Access | Times Cited: 129
Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa
Kristina Navrazhina, John W. Frew, Patricia Gilleaudeau, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 147, Iss. 6, pp. 2213-2224
Open Access | Times Cited: 92
Hidradenitis Suppurativa: Where We Are and Where We Are Going
Emanuele Scala, Sara Cacciapuoti, Natalie Garzorz‐Stark, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 2094-2094
Open Access | Times Cited: 91
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies*
Afsáneh Alavi, Iltefat Hamzavi, Kurt Brown, et al.
British Journal of Dermatology (2022) Vol. 186, Iss. 5, pp. 803-813
Open Access | Times Cited: 65
Altered Skin and Gut Microbiome in Hidradenitis Suppurativa
Siobhán McCarthy, Maurice Barrett, Shivashini Kirthi, et al.
Journal of Investigative Dermatology (2021) Vol. 142, Iss. 2, pp. 459-468.e15
Open Access | Times Cited: 64
Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions
Pedro Mendes‐Bastos, Ana Brasileiro, Pavel Kolkhir, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2355-2366
Open Access | Times Cited: 59
New and Emerging Targeted Therapies for Hidradenitis Suppurativa
Adela Markota Čagalj, Branka Marinović, Zrinka Bukvić Mokoš
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3753-3753
Open Access | Times Cited: 54
Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa
Samuel A Der Sarkissian, Schapoor Hessam, Joslyn S. Kirby, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 3, pp. 300-300
Open Access | Times Cited: 48
Therapeutic potential of targeting interleukin‐1 family cytokines in chronic inflammatory skin diseases*
Laura Calabrese, Zeno Fiocco, Takashi Satoh, et al.
British Journal of Dermatology (2022) Vol. 186, Iss. 6, pp. 925-941
Open Access | Times Cited: 44
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications
Helena Iznardo, L. Puig
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9479-9479
Open Access | Times Cited: 43
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 5, pp. 1099-1111
Open Access | Times Cited: 37
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
James G. Krueger, John W. Frew, Gregor B. E. Jemec, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 2, pp. 149-162
Open Access | Times Cited: 28
Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting
Pim Aarts, Johanna C. van Huijstee, Hessel H. van der Zee, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 4, pp. 677-684
Open Access | Times Cited: 27
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study
Joslyn S. Kirby, Martin M. Okun, Afsáneh Alavi, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 3, pp. 521-529
Open Access | Times Cited: 27
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study
Koen Dudink, Klasiena Bouwman, Yanqing Chen, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 5, pp. 601-609
Open Access | Times Cited: 26
Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm
Carlo Alberto Maronese, Chiara Moltrasio, Giovanni Genovese, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 5, pp. 525-545
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top